Magnus Ivarsson - Articles and news items

Sleep changes as translational pharmacodynamic biomarkers

Issue 5 2009, Past issues / 9 October 2009 /

Pharmacodynamic biomarkers in drug discovery: Developing a new drug is an expensive and time-consuming business1-3. A substantial part of the overall cost of drug development is the investment in molecules that fails at some point during the development process and it is necessary to identify these compounds as early as possible. Several different approaches are being pursued across the pharmaceutical industry to reduce the high attrition rates. One of these approaches is to identify biomarkers that are predictive of safety or efficacy and can be used in early clinical trials to build confidence that the molecule is engaging the intended target and is therefore worth investing more resources on4.

In vitro and in vivo techniques in CNS drug discovery

Issue 1 2006, Past issues / 2 February 2006 / Vahri Beaumont, Magnus Ivarsson and Keith A. Wafford, The Neuroscience Research Centre, Merck Sharp and Dohme, UK

In spite of an increased understanding of brain mechanisms in recent years, there has been a lack of major new drugs being registered for psychiatric and neurological conditions1,2. To prioritise drug discovery resources and provide early proof-of-concept studies for novel compounds and mechanisms, the pharmaceutical industry is increasingly focusing on trying to identify and develop early biological markers (biomarkers).


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...